Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms.
TLDR
In this article, inflammatory cytokines are considered to be responsible for a highly deleterious pathophysiologic process: the phenotypic transformation of polycythemia vera (PV) or essential thrombocythemia (ET), and the equivalent emergence of primary myelofibrosis (PMF).Abstract:
Myeloid neoplasms, including acute myeloid leukemia (AML), myeloproliferative neoplasms (MPNs), and myelodysplastic syndromes (MDS), feature clonal dominance and remodeling of the bone marrow niche in a manner that promotes malignant over non-malignant hematopoiesis. This take-over of hematopoiesis by the malignant clone is hypothesized to include hyperactivation of inflammatory signaling and overproduction of inflammatory cytokines. In the Ph-negative MPNs, inflammatory cytokines are considered to be responsible for a highly deleterious pathophysiologic process: the phenotypic transformation of polycythemia vera (PV) or essential thrombocythemia (ET) to secondary myelofibrosis (MF), and the equivalent emergence of primary myelofibrosis (PMF). Bone marrow fibrosis itself is thought to be mediated heavily by the cytokine TGF-β, and possibly other cytokines produced as a result of hyperactivated JAK2 kinase in the malignant clone. MF also features extramedullary hematopoiesis and progression to bone marrow failure, both of which may be mediated in part by responses to cytokines. In MF, elevated levels of individual cytokines in plasma are adverse prognostic indicators: elevated IL-8/CXCL8, in particular, predicts risk of transformation of MF to secondary AML (sAML). Tumor necrosis factor (TNF, also known as TNFα), may underlie malignant clonal dominance, based on results from mouse models. Human PV and ET, as well as MF, harbor overproduction of multiple cytokines, above what is observed in normal aging, which can lead to cellular signaling abnormalities separate from those directly mediated by hyperactivated JAK2 or MPL kinases. Evidence that NFκB pathway signaling is frequently hyperactivated in a pan-hematopoietic pattern in MPNs, including in cells outside the malignant clone, emphasizes that MPNs are pan-hematopoietic diseases, which remodel the bone marrow milieu to favor persistence of the malignancy. Clinical evidence that JAK2 inhibition by ruxolitinib in MF neither reliably reduces malignant clonal burden nor eliminates cytokine elevations, suggests targeting cytokine mediated signaling as a therapeutic strategy, which is being pursued in new clinical trials. Greater knowledge of inflammatory pathophysiology in MPNs can therefore contribute to the development of more effective therapy.read more
Citations
More filters
Journal ArticleDOI
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
Lionel Ades,Larisa Girshova,Vadim A Doronin,María Díez-Campelo,David Valcárcel,Suman Kambhampati,Nora Viniou,Dariusz Woszczyk,R. de Paz Arias,Argiris Symeonidis,Achilles Anagnostopoulos,Eduardo Munhoz,Uwe Platzbecker,Valeria Santini,Robert Fram,Ying Yuan,Sharon Friedlander,Douglas V. Faller,Mikkael A. Sekeres +18 more
TL;DR: The results underscore the importance of large, randomized controlled trials in these heterogeneous myeloid diseases and the value of remaining on therapy >3 cycles.
Journal ArticleDOI
Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia
TL;DR: In this paper , the PD-1/PD-L1 pathway activated in immune microenvironment, the milieu of BM shift to immunosuppressive, contributing to a clonal evolution of blasts.
Journal ArticleDOI
Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study.
Naveen Pemmaraju,Jacqueline S. Garcia,Jalaja Potluri,Jason G. Harb,Yan Sun,P. Soo Jung,Q. Qin,Srinivas K. Tantravahi,Srdan Verstovsek,Claire N. Harrison +9 more
TL;DR: This article showed that the addition of navitoclax to ruxolitinib induced a 35% or greater reduction in spleen volume (SVR35) and reduced symptoms in patients with myelofibrosis no longer benefiting from ruxolaxinib.
Journal ArticleDOI
Defining disease modification in myelofibrosis in the era of targeted therapy
TL;DR: In this article , the authors discuss recent clinical trial data of agents in development and dissect the potential for novel end points to act as disease modifying parameters, using the rationale garnered from latest clinical and scientific evidence, the authors propose a definition of disease modification in myelofibrosis.
Journal ArticleDOI
BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis.
Srdan Verstovsek,Haifa Kathrin Al-Ali,John Mascarenhas,Andrew C. Perkins,Alessandro M. Vannucchi,Sanjay R. Mohan,Bart L. Scott,Dariusz Woszczyk,Steffen Koschmieder,Regina Garcia-Delgado,Rejtő László,Jesse McGreivy,Wayne Rothbaum,Jean-Jacques Kiladjian +13 more
TL;DR: Navtemadlin (KRT-232) as mentioned in this paper restores p53 activity to drive apoptosis of wild-type TP53 tumor cells by inducing expression of pro-apoptotic Bcl-2 family proteins.
References
More filters
Journal ArticleDOI
IFNα activates dormant haematopoietic stem cells in vivo
Marieke A.G. Essers,Sandra Offner,William Blanco-Bose,Zoe Waibler,Ulrich Kalinke,Michel A. Duchosal,Andreas Trumpp +6 more
TL;DR: It is shown that in response to treatment of mice with interferon-α (IFNα), HSCs efficiently exit G0 and enter an active cell cycle, raising the possibility for new applications of type I interferons to target cancer stem cells.
Journal ArticleDOI
IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis.
Eugene Varfolomeev,John W. Blankenship,Sarah M. Wayson,Anna V. Fedorova,Nobuhiko Kayagaki,Parie Garg,Kerry Zobel,Jasmin N. Dynek,Linda O. Elliott,Heidi J.A. Wallweber,John A. Flygare,Wayne J. Fairbrother,Kurt Deshayes,Vishva M. Dixit,Domagoj Vucic +14 more
TL;DR: It is demonstrated that small-molecule IAP antagonists bind to select baculovirus IAP repeat (BIR) domains resulting in dramatic induction of auto-ubiquitination activity and rapid proteasomal degradation of c-IAPs.
Journal ArticleDOI
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
Srdan Verstovsek,Hagop M. Kantarjian,Ruben A. Mesa,Animesh Pardanani,Jorge Cortes-Franco,Deborah A. Thomas,Zeev Estrov,Jordan S. Fridman,Edward C Bradley,Susan Erickson-Viitanen,Kris Vaddi,Richard S. Levy,Ayalew Tefferi +12 more
TL;DR: INCB018424 was associated with marked and durable clinical benefits in patients with myelofibrosis for whom no approved therapies existed, and clinical benefits were associated with a marked diminution of levels of circulating inflammatory cytokines that are commonly elevated in myel ofibrosis.
Journal ArticleDOI
IAP Antagonists Target cIAP1 to Induce TNFα-Dependent Apoptosis
James E Vince,W. Wei-Lynn Wong,Nufail Khan,Rebecca Feltham,Diep Chau,Afsar U. Ahmed,Christopher A. Benetatos,Srinivas K. Chunduru,Stephen M. Condon,Mark A. McKinlay,Robert Brink,Martin Leverkus,Vinay Tergaonkar,Pascal Schneider,Bernard A. Callus,Frank Koentgen,David L. Vaux,John Silke +17 more
TL;DR: It is shown that apoptosis caused by an IAC is blocked by the caspase 8 inhibitor crmA and that IAP antagonists activate NF-κB signaling via inhibtion of cIAP1.
Journal ArticleDOI
Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells
Monica L. Guzman,Sarah J. Neering,Sarah J. Neering,Sarah J. Neering,Donna Upchurch,Donna Upchurch,Donna Upchurch,Barry Grimes,Barry Grimes,Barry Grimes,Dianna S. Howard,Dianna S. Howard,Dianna S. Howard,David A. Rizzieri,David A. Rizzieri,David A. Rizzieri,Selina M. Luger,Selina M. Luger,Selina M. Luger,Craig T. Jordan,Craig T. Jordan,Craig T. Jordan +21 more
TL;DR: Data indicate that primitive AML cells aberrantly express NF-kappaB and that the presence of this factor may provide unique opportunities to preferentially ablate LSCs.